Katherine Dodd, DO
Advanced Heart Failure and Transplant Cardiology · Columbus, OHNPI 1568738557
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (57.1%), food and beverage and education — rather than concentrated in one kind of arrangement. Medtronic accounts for 62.4% of it on its own, with 13 other manufacturers making up the rest. Reporting peaked in 2022 at $1,462 and has fallen 94.1% since, to $86 in 2025. That places this record below the midpoint for advanced heart failure and transplant cardiology clinicians in OH, where the typical reported total is $4,421.
Across 37 payments — averaging $97.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Abiomed$513
- Abbott$239
- Boston Scientific$226
- AstraZeneca$100
- Impulse Dynamics (USA) Inc.$74
- plus $208 from 8 others
Across 12 payments — averaging $2512.44 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Impulse Dynamics (USA) Inc.$30K
What the payments were for
- Travel & lodging$2,06557%
- Food & beverage$1,37938%
- Education$1735%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 11 | $2,257 |
| Abiomed | 2 | $513 |
| Abbott | 5 | $239 |
| Boston Scientific | 2 | $226 |
| AstraZeneca | 6 | $100 |
| Impulse Dynamics (USA) Inc. | 1 | $74 |
| Kestra Medical Technology Services, Inc. | 1 | $45 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $38 |
| Novartis | 2 | $28 |
| Daiichi Sankyo Inc. | 1 | $24 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Merck | 1 | $18 |
| Alnylam Pharmaceuticals Inc. | 1 | $18 |
| Pfizer | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$3,616 in reported general payments places this provider in the 40th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
See all advanced heart failure and transplant cardiology providers in Ohio →
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 33 | $766,757 |
| EntrestoSacubitril/Valsartan | 227 | $275,298 |
| OpsumitMacitentan | 12 | $148,312 |
| FarxigaDapagliflozin Propanediol | 83 | $79,621 |
| JardianceEmpagliflozin | 55 | $70,320 |
| Bumetanide | 112 | $9,788 |
| Torsemide | 216 | $5,792 |
| Metoprolol Succinate | 341 | $4,850 |
| Spironolactone | 382 | $2,750 |
| Eplerenone | 16 | $1,994 |
| Losartan Potassium | 226 | $1,901 |
| Carvedilol | 126 | $1,017 |
| Klor-Con M20Potassium Chloride | 23 | $762 |
| Valsartan | 23 | $672 |
| Furosemide | 130 | $587 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax | $16 | $766,75733 claims |
| NovartisEntresto | $28 | $275,298227 claims |
| AstraZenecaFarxiga | $100 | $79,62183 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 40th percentile of 62 advanced heart failure and transplant cardiology providers in Ohio.
Other advanced heart failure and transplant cardiology in Columbus
- William AbrahamColumbus$802K
- Rami KahwashColumbus$379K
- Beth ForemanColumbus$28K
- Vaiibhav PatelColumbus$10K
- Ray HershbergerColumbus$6K
- Anupam BasurayColumbus$6K
- Ajay VallakatiColumbus$4K
- Lindsay CastleColumbus$3K
- Rodolfo Denadai BenattiColumbus$2K
- Yaquta KakaColumbus$859
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.